Full Press Release Details
RICHMOND, Va.,Oct. 28, 2025/PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference:
INDV Positive Sentiment
Indivior to Participate in the Stifel 2025 Healthcare Conference
Key Takeaway: Indivior PLC announced its participation in the Stifel 2025 Healthcare Conference. The company is dedicated to developing treatments for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease. Indivior continues to build its portfolio and pipeline of product candidates in this area.
Price reaction · baseline $24.62 (2025-10-28T14:59:00.000Z) · hit during market hours · 1 other INDV headline(s) in the window, move may be shared
day 0 close · peak
+1.2%
Market Sentiment Analysis
POSITIVE FACTORS
- Indivior is actively participating in healthcare conferences.
- The company is focused on addressing opioid use disorder.
- Indivior has a pipeline of product candidates for OUD treatments.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
5.4%
average across 2 past catalysts
Lead asset
RBP-6000
Phase 3 · Opioid Use Disorder
Frequently Asked Questions
What conference will Indivior participate in?
Indivior will participate in the Stifel 2025 Healthcare Conference.
What is Indivior's focus in healthcare?
Indivior focuses on developing medicines for opioid use disorder (OUD).
What is Indivior's vision for OUD treatment?
Indivior aims to provide evidence-based treatment for OUD and recognize it as a chronic disease.
Does Indivior have a pipeline for OUD treatments?
Yes, Indivior has a pipeline of product candidates for opioid use disorder treatments.